Leprosy Mailing List – February 2, 2015
Ref.: (LML) How Efficacious is MDT
From: Joseph Kawuma, Kampala, Uganda
Dear Pieter,
As usual, this is evolving into a very interesting and informative discussion.
I am concerned that several suggestions do not specify the type or level of settings for implementation. Today we are in a world where some lucky patients can access experienced clinicians with facilities like measuring anti-PGL1 antibodies and there are others where there are still hardly any easily accessible, functional basic health services to talk about. When recommendations are made, they should include those that are feasible in the less than ideal settings where (unfortunately) the majority of people receiving leprosy treatment (at least in Africa) are found. There are concerns about not only the completion of the relatively short MDT regimens but also the organisation of follow up after MDT as well as the diagnosis and management of relapses in those same settings. How shall we derive the answer to the question "how efficacious is MDT" in those settings?
H Joseph Kawuma
GLRA, Uganda
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
 | This email has been checked for viruses by Avast antivirus software. |
No comments:
Post a Comment